Lexicon Pharmaceuticals (NASDAQ:LXRX) adds US$51m to market cap in the past 7 days, though investors from five years ago are still down 69%

Long term investing can be profitable, but not always immune to losses. For instance, Lexicon Pharmaceuticals' stock has declined significantly over five years, indicating high risk due to low revenue and profitability. Shareholders must consider company stability before investing.